Cargando…
The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer
Epigenetic alterations in colorectal cancer (CRC) cause important differences in the underlying tumor biology and aggressiveness. DNA hypermethylation is central for the development of CRC but the prognostic impact remains elusive. We aimed to assess the association between cell-free hypermethylated...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805532/ https://www.ncbi.nlm.nih.gov/pubmed/29467946 http://dx.doi.org/10.18632/oncotarget.24097 |
_version_ | 1783298990365736960 |
---|---|
author | Rasmussen, Simon Ladefoged Krarup, Henrik Bygum Sunesen, Kåre Gotschalck Johansen, Martin Berg Stender, Mogens Tornby Pedersen, Inge Søkilde Madsen, Poul Henning Thorlacius-Ussing, Ole |
author_facet | Rasmussen, Simon Ladefoged Krarup, Henrik Bygum Sunesen, Kåre Gotschalck Johansen, Martin Berg Stender, Mogens Tornby Pedersen, Inge Søkilde Madsen, Poul Henning Thorlacius-Ussing, Ole |
author_sort | Rasmussen, Simon Ladefoged |
collection | PubMed |
description | Epigenetic alterations in colorectal cancer (CRC) cause important differences in the underlying tumor biology and aggressiveness. DNA hypermethylation is central for the development of CRC but the prognostic impact remains elusive. We aimed to assess the association between cell-free hypermethylated DNA and stage and survival in colorectal cancer (CRC). We analyzed pre-treatment plasma samples from 193 patients with CRC. Thirty gene-promoter regions were analyzed using methylation specific PCR. We compared the median number (range) of hypermethylated promoter regions with CRC stage, and constructed a multivariable Cox-regression model adjusted for stage, to evaluate the added prognostic information. The median number of hypermethylated promoter regions was nine (0-28) in patients with distant metastasis compared to five (0-19) in patients without metastatic disease (p < 0.0001). The majority of the hypermethylated promoter regions inferred a poor prognosis. Cox-regression analysis adjusted for patient age, sex, pre-treatment CEA-levels, and disease stage, showed that RARB (HR = 1.99, 95% CI [1.07, 3.72]) and RASSF1A (HR = 3.35, 95% CI [1.76, 6.38]) hypermethylation inferred a significant effect on survival. The risk of metastasis increase with the number of cell-free hypermethylated promoter regions. The presence of RARB and RASSF1A hypermethylation indicated aggressive disease, regardless of stage at the time of diagnosis. |
format | Online Article Text |
id | pubmed-5805532 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-58055322018-02-21 The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer Rasmussen, Simon Ladefoged Krarup, Henrik Bygum Sunesen, Kåre Gotschalck Johansen, Martin Berg Stender, Mogens Tornby Pedersen, Inge Søkilde Madsen, Poul Henning Thorlacius-Ussing, Ole Oncotarget Research Paper Epigenetic alterations in colorectal cancer (CRC) cause important differences in the underlying tumor biology and aggressiveness. DNA hypermethylation is central for the development of CRC but the prognostic impact remains elusive. We aimed to assess the association between cell-free hypermethylated DNA and stage and survival in colorectal cancer (CRC). We analyzed pre-treatment plasma samples from 193 patients with CRC. Thirty gene-promoter regions were analyzed using methylation specific PCR. We compared the median number (range) of hypermethylated promoter regions with CRC stage, and constructed a multivariable Cox-regression model adjusted for stage, to evaluate the added prognostic information. The median number of hypermethylated promoter regions was nine (0-28) in patients with distant metastasis compared to five (0-19) in patients without metastatic disease (p < 0.0001). The majority of the hypermethylated promoter regions inferred a poor prognosis. Cox-regression analysis adjusted for patient age, sex, pre-treatment CEA-levels, and disease stage, showed that RARB (HR = 1.99, 95% CI [1.07, 3.72]) and RASSF1A (HR = 3.35, 95% CI [1.76, 6.38]) hypermethylation inferred a significant effect on survival. The risk of metastasis increase with the number of cell-free hypermethylated promoter regions. The presence of RARB and RASSF1A hypermethylation indicated aggressive disease, regardless of stage at the time of diagnosis. Impact Journals LLC 2018-01-09 /pmc/articles/PMC5805532/ /pubmed/29467946 http://dx.doi.org/10.18632/oncotarget.24097 Text en Copyright: © 2018 Rasmussen et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Rasmussen, Simon Ladefoged Krarup, Henrik Bygum Sunesen, Kåre Gotschalck Johansen, Martin Berg Stender, Mogens Tornby Pedersen, Inge Søkilde Madsen, Poul Henning Thorlacius-Ussing, Ole The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer |
title | The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer |
title_full | The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer |
title_fullStr | The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer |
title_full_unstemmed | The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer |
title_short | The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer |
title_sort | prognostic efficacy of cell-free dna hypermethylation in colorectal cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805532/ https://www.ncbi.nlm.nih.gov/pubmed/29467946 http://dx.doi.org/10.18632/oncotarget.24097 |
work_keys_str_mv | AT rasmussensimonladefoged theprognosticefficacyofcellfreednahypermethylationincolorectalcancer AT kraruphenrikbygum theprognosticefficacyofcellfreednahypermethylationincolorectalcancer AT sunesenkaregotschalck theprognosticefficacyofcellfreednahypermethylationincolorectalcancer AT johansenmartinberg theprognosticefficacyofcellfreednahypermethylationincolorectalcancer AT stendermogenstornby theprognosticefficacyofcellfreednahypermethylationincolorectalcancer AT pederseningesøkilde theprognosticefficacyofcellfreednahypermethylationincolorectalcancer AT madsenpoulhenning theprognosticefficacyofcellfreednahypermethylationincolorectalcancer AT thorlaciusussingole theprognosticefficacyofcellfreednahypermethylationincolorectalcancer AT rasmussensimonladefoged prognosticefficacyofcellfreednahypermethylationincolorectalcancer AT kraruphenrikbygum prognosticefficacyofcellfreednahypermethylationincolorectalcancer AT sunesenkaregotschalck prognosticefficacyofcellfreednahypermethylationincolorectalcancer AT johansenmartinberg prognosticefficacyofcellfreednahypermethylationincolorectalcancer AT stendermogenstornby prognosticefficacyofcellfreednahypermethylationincolorectalcancer AT pederseningesøkilde prognosticefficacyofcellfreednahypermethylationincolorectalcancer AT madsenpoulhenning prognosticefficacyofcellfreednahypermethylationincolorectalcancer AT thorlaciusussingole prognosticefficacyofcellfreednahypermethylationincolorectalcancer |